Veralox Therapeutics
Veralox is a clinical stage biotechnology company focused on developing first-in-class small molecule therapeutics targeting the 12-Lipoxygenase and cGAS pathways to treat life-threatening immuno-inflammatory diseases. With a proven track record of over 30 development candidates, 22 INDs, and 10 NDAs, Veralox aims to improve clinical outcomes for diseases like Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D). The company is advancing its pipeline with innovative therapies and strategic acquisitions, such as the exclusive option to acquire Nudge Therapeutics.
Industries
Nr. of Employees
small (1-50)
Products
VLX-1005
A first-in-class small molecule drug targeting 12-Lipoxygenase, developed for treating Heparin-Induced Thrombocytopenia (HIT). It has received Fast Track designation from the FDA.
VLX-2000
A series of small molecule therapeutics targeting Type 1 Diabetes and other undisclosed indications.
VLX-1005
A first-in-class small molecule drug targeting 12-Lipoxygenase, developed for treating Heparin-Induced Thrombocytopenia (HIT). It has received Fast Track designation from the FDA.
VLX-2000
A series of small molecule therapeutics targeting Type 1 Diabetes and other undisclosed indications.
News & Updates
Exclusive agreement to acquire Nudge Therapeutics includes their series of cGAS inhibitors, which prevent the overproduction of Type 1 interferons.
Veralox received new designation for treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) disorders, complementing FDA Orphan Drug and Fast Track designations for VLX-1005.
The company announced a new financing of $24 million to fund the Phase 2 clinical trial of VLX-1005 for HIT.
Veralox's VLX-1005, a small molecule 12-LOX inhibitor, received Fast Track designation to treat HIT.
Veralox announced the appointment of Lisa Beck as Chief Business Officer.
Veralox announced the appointment of Michael S. Hanna as Chief Medical Officer.
Exclusive agreement to acquire Nudge Therapeutics includes their series of cGAS inhibitors, which prevent the overproduction of Type 1 interferons.
Veralox received new designation for treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) disorders, complementing FDA Orphan Drug and Fast Track designations for VLX-1005.
The company announced a new financing of $24 million to fund the Phase 2 clinical trial of VLX-1005 for HIT.
Veralox's VLX-1005, a small molecule 12-LOX inhibitor, received Fast Track designation to treat HIT.
Veralox announced the appointment of Lisa Beck as Chief Business Officer.
Veralox announced the appointment of Michael S. Hanna as Chief Medical Officer.